Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.
You may also be interested in...
With Corlanor Approval, Amgen Kicks Its CV Push Into High Gear
Amgen will launch the heart failure drug within one week, creating a chance to build rapport with cardiologists ahead of potential launch of the PCSK9 blocker evolocumab later this year.
Amgen Positions Ivabradine As A Foot In The Door Ahead Of PCSK9 Launch
Amgen executives laid out the case for the heart failure candidate ivabradine, which will serve as a foundation for the launch of the company’s highly anticipated PCSK9 inhibitor, during a presentation at AHA. The company also presented the first 52-week data on evolocumab.
Amgen Positions Ivabradine As A Foot In The Door Ahead Of PCSK9 Launch
Amgen executives laid out the case for the heart failure candidate ivabradine, which will serve as a foundation for the launch of the company’s highly anticipated PCSK9 inhibitor, during a presentation at AHA. The company also presented the first 52-week data on evolocumab.